CPJE Top 200 Drugs Brand and Generic: Foundational Knowledge
How the Top 200 List is Curated for the CPJE
The California Board of Pharmacy does not release a static document titled the CPJE high yield medications list. Instead, the exam reflects current prescribing trends within California and the United States, emphasizing medications with narrow therapeutic indices, high potential for error, or significant legal restrictions. The curation process for the exam involves a focus on the most commonly prescribed agents across major therapeutic classes such as cardiovascular, psychotropic, and anti-infective categories. However, the CPJE often includes "legacy" drugs that remain clinically relevant—such as warfarin or digoxin—alongside newer biologics and biosimilars. Candidates should anticipate questions on agents that have recently transitioned to over-the-counter status or those that are subject to specific California-mandated counseling requirements. The scoring system often weighs safety-related questions heavily, meaning a failure to recognize a brand name associated with a high-risk medication can lead to an incorrect answer on a critical "Minimum Competency" question.
Study Strategies for Brand-Generic Fluency
Developing pharmacy brand generic names CPJE fluency requires a bidirectional study approach. Candidates often make the mistake of only learning the generic name for a given brand; however, the exam frequently presents the brand name in a patient profile and asks for a contraindication based on the generic's mechanism of action. A successful strategy involves grouping medications by their CPJE drug classification study clusters. For instance, rather than memorizing ACE inhibitors in isolation, study them as a group (the "-pril" suffix) while highlighting unique brand-name outliers like Zestril versus Altace. Utilize the "Look-Alike Sound-Alike" (LASA) list provided by the Institute for Safe Medication Practices (ISMP), as the CPJE often tests your ability to distinguish between confusing pairs like hydralazine and hydroxyzine. Real exam scenarios frequently involve a patient presenting with a side effect, requiring the candidate to identify the offending agent from a list of five brand names, making instantaneous recognition a non-negotiable skill.
Cardiovascular and Renal Medications
Antihypertensives by Class (ACEi, ARB, CCB, etc.)
Cardiovascular agents constitute a massive portion of the common drugs on CPJE exam. When studying Angiotensin-Converting Enzyme Inhibitors (ACEi) and Angiotensin Receptor Blockers (ARBs), focus on the risk of angioedema and the specific contraindication in pregnancy (Boxed Warning: Fetal Toxicity). For Calcium Channel Blockers (CCBs), distinguish between the dihydropyridines (e.g., amlodipine/Norvasc) and non-dihydropyridines (e.g., diltiazem/Cardizem). The CPJE frequently tests the clinical distinction that non-dihydropyridines are potent CYP3A4 inhibitors and possess negative inotropic effects, making them cautious choices in heart failure. Diuretics also require precision; you must differentiate the site of action for Thiazides (Distal Convoluted Tubule) versus Loop diuretics (Ascending Limb of the Loop of Henle). Expect questions regarding the "sulfa" allergy cross-reactivity with loop diuretics and the specific electrolyte imbalances, such as hypokalemia or hyperuricemia, which can trigger gout flares.
Anticoagulants and Antiplatelets
The CPJE places a high premium on anticoagulation safety. Candidates must know the CPJE medication review guide highlights for Direct Oral Anticoagulants (DOACs) like apixaban (Eliquis) and rivaroxaban (Xaveralto), particularly their dosing adjustments for renal impairment using the Cockcroft-Gault equation. Warfarin (Coumadin) remains a high-yield topic due to its extensive drug-food interactions (Vitamin K consistency) and its narrow Therapeutic Index, requiring frequent INR monitoring. Antiplatelets like clopidogrel (Plavix) involve pharmacogenomic considerations; specifically, the requirement for CYP2C19 metabolism to its active form. Failure to recognize that a patient taking a Proton Pump Inhibitor (PPI) like omeprazole may have reduced clopidogrel efficacy is a classic CPJE clinical trap. Candidates should also be familiar with the reversal agents for these medications, such as idarucizumab (Praxbind) for dabigatran.
Heart Failure and Dyslipidemia Agents
For dyslipidemia, the HMG-CoA reductase inhibitors (Statins) are essential. Knowledge of which statins are high-intensity (Atorvastatin 40-80mg, Rosuvastatin 20-40mg) is frequently assessed. You must also identify which statins can be taken at any time of day versus those requiring evening administration due to the short half-life of the enzyme (e.g., simvastatin/Zocor). Heart failure therapy has evolved to include the Angiotensin Receptor-Neprilysin Inhibitor (ARNI) sacubitril/valsartan (Entresto). A critical exam point is the 36-hour washout period required when switching from an ACE inhibitor to an ARNI to prevent the accumulation of bradykinin and subsequent angioedema. Additionally, the role of Beta-Blockers in heart failure is limited to specific agents—metoprolol succinate, carvedilol, and bisoprolol—and the CPJE may test your ability to catch an inappropriate prescription of metoprolol tartrate for chronic heart failure management.
Insulins and Non-Insulin Diabetes Medications
Diabetes management is a cornerstone of the CPJE. You must memorize the onset, peak, and duration for all insulin types, from rapid-acting (Aspart/NovoLog) to ultra-long-acting (Degludec/Tresiba). The exam often tests your ability to calculate an Insulin-to-Carbohydrate Ratio or a Correction Factor using the Rule of 500 or Rule of 1800. For non-insulin agents, focus on the unique side effects of SGLT2 inhibitors (e.g., empagliflozin/Jardiance), such as the risk of mycotic infections and euglycemic ketoacidosis. GLP-1 agonists (e.g., liraglutide/Victoza) carry a Boxed Warning for Thyroid C-cell tumors. Metformin (Glucophage) remains a high-priority drug; candidates must know the Renal Function Cutoffs (eGFR < 30 mL/min/1.73m² is a contraindication) and the risk of Vitamin B12 deficiency during long-term use.
Thyroid and Osteoporosis Treatments
Levothyroxine (Synthroid) is one of the most frequently prescribed drugs and a common fixture on the exam. Key counseling points include taking it on an empty stomach, 30-60 minutes before breakfast, to ensure optimal absorption. For osteoporosis, bisphosphonates like alendronate (Fosamax) require specific administration instructions to prevent esophageal erosion: the patient must remain upright for at least 30 minutes and take the medication with a full glass of plain water. The CPJE may also ask about the rare but serious side effect of Osteonecrosis of the Jaw (ONJ) or atypical femur fractures. Candidates should also recognize the monoclonal antibody denosumab (Prolia) and its dosing frequency (every 6 months) compared to the daily or weekly dosing schedules of oral bisphosphonates.
Corticosteroids and Their Tapers
Systemic corticosteroids like prednisone (Deltasone) and methylprednisolone (Medrol) are tested on their short-term and long-term side effect profiles. Short-term effects include hyperglycemia, fluid retention, and mood changes (steroid psychosis), while long-term use leads to Cushingoid features, osteoporosis, and adrenal suppression. The CPJE emphasizes the clinical necessity of a steroid taper when therapy exceeds 14 days to allow the Hypothalamic-Pituitary-Adrenal (HPA) axis to recover. Candidates should be able to identify a Medrol Dosepak's specific tapering schedule (24mg to 4mg over 6 days) and recognize that abrupt cessation of high-dose steroids can lead to an Addisonian crisis, characterized by hypotension and cardiovascular collapse.
Central Nervous System and Psychotropic Agents
Antidepressants (SSRI, SNRI, TCA)
Psychotropic medications are heavily regulated in California, making them high-yield for both clinical and law portions of the CPJE. Selective Serotonin Reuptake Inhibitors (SSRIs) like fluoxetine (Prozac) and sertraline (Zoloft) are first-line, but you must know their side effects, including sexual dysfunction and hyponatremia. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) like venlafaxine (Effexor) can cause dose-dependent increases in blood pressure. Tricyclic Antidepressants (TCAs) like amitriptyline (Elavil) are often tested on their anticholinergic toxidrome (dry mouth, blurred vision, urinary retention) and their cardiotoxicity in overdose (QT prolongation). A critical exam point is the washout period for Monoamine Oxidase Inhibitors (MAOIs)—usually 14 days—to prevent Serotonin Syndrome when switching to another serotonergic agent.
Antipsychotics and Mood Stabilizers
First-generation antipsychotics (e.g., haloperidol) are associated with Extrapyramidal Symptoms (EPS) and Tardive Dyskinesia due to potent D2 antagonism. Second-generation antipsychotics (SGAs) like quetiapine (Seroquel) and olanzapine (Zyprexa) have a higher risk of metabolic syndrome (weight gain, dyslipidemia, hyperglycemia). Clozapine (Clozaril) is a special case on the CPJE; candidates must be familiar with the REMS program requirements for Absolute Neutrophil Count (ANC) monitoring (ANC must be ≥ 1500/mm³ to initiate). Mood stabilizers like lithium (Lithobid) require knowledge of their narrow therapeutic range (0.6–1.2 mEq/L) and the factors that increase lithium levels, such as NSAID use, dehydration, and low-sodium diets.
Antiepileptics and Drugs for Pain Management
Antiepileptic drugs (AEDs) are frequently tested for their kinetics and side effects. Phenytoin (Dilantin) follows Michaelis-Menten kinetics, where small dose increases can lead to disproportionate increases in serum levels. Key side effects include gingival hyperplasia and nystagmus. Valproic acid (Depakote) is notable for hepatotoxicity and thrombocytopenia. In pain management, the focus shifts to opioids and the legal requirements for C-II prescriptions in California. Morphine Milligram Equivalents (MME) calculations are vital for assessing overdose risk. Candidates must also know the specific indications for adjuvant therapies, such as gabapentin (Neurontin) for neuropathic pain or sumatriptan (Imitrex) for acute migraine, including the contraindication of triptans in patients with ischemic heart disease.
Anti-Infectives and Immunologics
Common Antibiotics and Their Spectra
Antibiotic stewardship is a major theme on the CPJE. You must know the coverage spectrum for common agents: for example, ceftriaxone (Rocephin) covers most gram-positives and gram-negatives but lacks activity against Pseudomonas. Conversely, piperacillin/tazobactam (Zosyn) and cefepime (Maxipime) are the go-to agents for Pseudomonas. Fluoroquinolones like ciprofloxacin (Cipro) carry multiple Boxed Warnings, including tendon rupture and peripheral neuropathy. The exam also tests specific counseling points, such as avoiding divalent cations (calcium, iron, magnesium) with tetracyclines and fluoroquinolones due to chelation. Be prepared to identify the drug of choice for common infections, such as nitrofurantoin (Macrobid) for uncomplicated cystitis, provided the CrCl is above 30 mL/min.
Antivirals for HIV and Hepatitis
Antiretroviral Therapy (ART) for HIV is a specialized but high-yield area. Candidates should recognize the components of common single-tablet regimens like Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide). Knowledge of the specific side effects of the drug classes is essential, such as the risk of bone mineral density loss and renal impairment with Tenofovir Disoproxil Fumarate (TDF) compared to the safer Tenofovir Alafenamide (TAF). For Hepatitis C, Direct-Acting Antivirals (DAAs) like sofosbuvir/velpatasvir (Epclusa) have transformed treatment, but they require screening for Hepatitis B reactivation before initiation. The CPJE may also test the interaction between DAAs and acid-suppressing agents like PPIs, which can significantly decrease the absorption of certain antivirals.
Vaccines and Biologic Agents
Vaccination schedules and storage requirements are frequently tested. For example, you must know that the Shingrix vaccine is indicated for adults ≥ 50 years and is a two-dose series. Biologic agents, particularly Tumor Necrosis Factor (TNF) inhibitors like adalimumab (Humira) and etanercept (Enbrel), are tested on their requirement for Tuberculosis (TB) screening prior to use. As biosimilars become more common, the CPJE may ask about the Purple Book and the interchangeability of biologics. Candidates should also be aware of the "live" vaccines (e.g., MMR, Varicella, Flumist) and the contraindications for their use in immunocompromised patients or during pregnancy.
Gastrointestinal, Respiratory, and Miscellaneous
GERD, IBD, and Antiemetic Drugs
Gastrointestinal medications often involve long-term safety concerns. Proton Pump Inhibitors (PPIs) like esomeprazole (Nexium) are associated with increased risks of C. difficile-associated diarrhea, hypomagnesemia, and fractures. For Inflammatory Bowel Disease (IBD), understand the role of mesalamine (Asacol) as a maintenance therapy. Antiemetics are categorized by their mechanism: 5-HT3 receptor antagonists like ondansetron (Zofran) are standard for chemotherapy-induced nausea but can cause QT prolongation. In contrast, dopamine antagonists like promethazine (Phenergan) carry a Boxed Warning for severe tissue injury if administered intra-arterially or subcutaneously and are contraindicated in children under two years of age due to fatal respiratory depression.
Asthma/COPD Inhalers and Controllers
Respiratory therapy requires distinguishing between Rescue Inhalers (SABAs like albuterol/ProAir) and Maintenance Controllers. Inhaled Corticosteroids (ICS) like fluticasone (Flovent) require counseling on rinsing the mouth to prevent oral candidiasis (thrush). For COPD, Long-Acting Muscarinic Antagonists (LAMAs) like tiotropium (Spiriva) are foundational. The CPJE often tests your ability to identify the components of combination inhalers, such as Advair (fluticasone/salmeterol) or Symbicort (budesonide/formoterol). Understanding the Global Initiative for Asthma (GINA) guidelines—which now recommend against SABA-only treatment in favor of PRN low-dose ICS-formoterol—is crucial for answering contemporary clinical questions on the exam.
Chemotherapy Support and Topical Agents
While the CPJE does not require deep knowledge of complex oncological protocols, it does test supportive care. Candidates should know the role of filgrastim (Neupogen) for neutropenia and erythropoietin-stimulating agents (ESAs) like epoetin alfa (Epogen) for anemia, including the hemoglobin cutoff (< 10 g/dL) for initiation in cancer patients. Topical agents are also high-yield, particularly high-potency vs. low-potency corticosteroids. Clobetasol propionate is ultra-high potency and should not be used on the face or skin folds, whereas hydrocortisone is low potency and safer for sensitive areas. The exam may also cover topical retinoids for acne and the mandatory iPLEDGE program requirements for oral isotretinoin (Claravis).
Applying Drug Knowledge to CPJE Questions
Recognizing Drugs in Patient Profiles
The CPJE utilizes a Patient Profile format for many of its questions. This means you will not just see a question about a drug; you will see a list of medications, a set of lab values, and a patient history. Success depends on the ability to scan a profile and immediately identify the CPJE top 200 drugs brand and generic names present. For example, if a patient is taking "Zestril" and the labs show a serum potassium of 5.8 mEq/L, you must recognize Zestril as lisinopril and identify that the medication is contributing to the hyperkalemia. This level of recognition must be instinctual to allow enough time for the more complex law-based questions that often follow clinical scenarios.
Answering Questions on Side Effects and Interactions
When the exam asks about side effects, it often focuses on those that are "dose-limiting" or "life-threatening." You must be able to link a drug to its specific toxicity: for example, amiodarone (Cordarone) and its multi-organ toxicities (pulmonary fibrosis, thyroid dysfunction, hepatotoxicity). Drug-drug interactions on the CPJE frequently involve the Cytochrome P450 system. You must know the "Big Inducers" (e.g., rifampin, carbamazepine, St. John's Wort) and "Big Inhibitors" (e.g., grapefruit juice, protease inhibitors, azole antifungals). A common question type involves a patient stabilized on a drug like warfarin or theophylline who then starts an inhibitor, leading to toxic levels of the original medication.
Identifying Therapeutic Duplications and Alternatives
Therapeutic duplication is a major safety focus of the California Board. You may be presented with a profile where a patient is taking both a brand-name drug and its generic equivalent (e.g., Norvasc and amlodipine) or two drugs in the same class (e.g., two different SSRIs). The CPJE requires you to identify these errors and suggest the appropriate intervention. Furthermore, you must know therapeutic alternatives for patients with allergies or contraindications. If a patient has a documented anaphylactic allergy to penicillin, you must be able to identify which cephalosporins might have cross-reactivity and which agents, like azithromycin or clindamycin, would be safe alternatives. This synthetic thinking—combining drug names, classes, and safety data—is the hallmark of a candidate prepared for the CPJE.